<DOC>
	<DOCNO>NCT00524953</DOCNO>
	<brief_summary>The primary goal tho study assess safety Ultraviolet ( UV ) Phototherapy Prevention Graft versus Host Disease allogeneic stem cell transplantation ( Phase I - Clinical trial ) . Following allogeneic BMT , patient place standard GVHD preventive therapy ( cyclosporine ) . Secondary goal - - monitoring immune system recovery - influence stem cell origin therapy and/orGVHD prevention - influence UV-c treatment survival clinical data sample collect , UV-c therapy , 100 day discharge &amp; 6 month discharge - examine long-term effect UV-c treatment patient 's GVHD status .</brief_summary>
	<brief_title>Phase I Clinical Trial Assess Safety UV Phototherapy Prevention GVHD Post Allogeneic SCT</brief_title>
	<detailed_description>Treatment give portable , easy operate device name `` EUMATRON '' . device contain UV- lamp . 250 cc blood peripheric vein go device bottle Low dose Heparin return patient 's body . procedure take ~20 minute .</detailed_description>
	<criteria>patient post non T cell deplete allogeneic stem cell transplantation morbidity unrelated GVHD patient hemodynamic unstable condition acute uncontrolled bleed patient undergoing dialysis</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>allogeneic bone marrow transplantation</keyword>
	<keyword>non-T-cell deplete</keyword>
	<keyword>UV-c</keyword>
	<keyword>GVHD</keyword>
</DOC>